Last reviewed · How we verify

Levobupivacaine with epinephrine

Pontificia Universidad Catolica de Chile · FDA-approved active Small molecule

Levobupivacaine blocks sodium channels in nerve cell membranes to produce local anesthesia, while epinephrine causes vasoconstriction to prolong the anesthetic effect and reduce systemic absorption.

Levobupivacaine blocks sodium channels in nerve cell membranes to produce local anesthesia, while epinephrine causes vasoconstriction to prolong the anesthetic effect and reduce systemic absorption. Used for Local and regional anesthesia for surgical and diagnostic procedures, Infiltration anesthesia, Nerve blocks.

At a glance

Generic nameLevobupivacaine with epinephrine
SponsorPontificia Universidad Catolica de Chile
Drug classLocal anesthetic with vasoconstrictor
TargetVoltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Levobupivacaine is the S-enantiomer of bupivacaine, a long-acting local anesthetic that reversibly inhibits sodium influx into nerve fibers, preventing depolarization and action potential propagation. Epinephrine acts as an alpha-1 adrenergic agonist, causing vasoconstriction at the injection site that slows drug clearance, extends duration of action, and reduces peak plasma concentrations of the local anesthetic.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: